Welcome to our dedicated page for PMGC Holdings news (Ticker: elab), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
PMGC Holdings Inc. (NASDAQ: ELAB) delivers innovative solutions across biopharmaceuticals, medical aesthetics, and strategic investments. This news hub provides investors with centralized access to all corporate announcements, regulatory updates, and market developments.
Track timely updates on clinical trial progress, partnership agreements, and financial performance. Find press releases covering engineered probiotic therapies for metabolic health, advancements in aesthetic medicine technologies, and strategic moves in fire prevention and energy sectors.
Our curated news collection enables informed decision-making through verified updates on FDA milestones, acquisition activity, and leadership changes. Bookmark this page for ongoing insights into ELAB's diversified growth strategy across healthcare and essential infrastructure markets.
PMGC Holdings (NASDAQ: ELAB) has provided an update on its capital structure, highlighting its debt-free status and strong financial position. The company currently has 4,042,295 common shares outstanding, with 4,931 stock options at a weighted-average exercise price of $304 per share, and 979,814 warrants at a weighted-average exercise price of $4.91.
Recent capital raises include an $8.0 million S-1 offering in September 2024 and a $1.9 million warrant inducement offering in January 2025. The company operates through three main subsidiaries: NorthStrive Biosciences (focused on aesthetic medicines), PMGC Research (utilizing Canadian research grants), and PMGC Capital (a multi-strategy investment firm).
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has submitted a pre-IND meeting request to the FDA for EL-22, a novel myostatin-targeting therapy designed to preserve muscle during weight loss treatments. The company expects a Type B pre-IND meeting with the FDA in Q2 2025 to discuss nonclinical studies and clinical development plans for EL-22's use in combination with GLP-1 receptor agonists for obesity treatment.
EL-22 is a patent-pending engineered probiotic that expresses myostatin on its surface. Preclinical studies in mdx mice showed significant physiological and functional improvements, and a Phase 1 trial in South Korea demonstrated general safety and tolerability in healthy volunteers. The company plans to file an IND application in 2025 to begin clinical trials evaluating EL-22's combination with GLP-1 receptor agonists.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), provided updates on its obesity drug candidates EL-22 and EL-32, designed to optimize fat loss while preserving muscle mass during weight loss therapies, including GLP-1 receptor agonists.
The company is preparing for a pre-IND meeting with the FDA in Q2 2025 for EL-22, a myostatin-engineered probiotic that has completed Phase 1 trials in South Korea showing general safety. Northstrive is currently seeking a U.S.-based cGMP manufacturing partner and aims to file an IND application in 2025.
For EL-32, a pre-clinical engineered probiotic expressing dual myostatin & activin-A inhibitors, Northstrive has engaged a CRO to conduct studies evaluating its effectiveness both alone and in combination with semaglutide in diet-induced obese mice.
PMGC Holdings (Nasdaq: ELAB) has announced that its subsidiary, PMGC Capital , has initiated portfolio building with strategic investments in fire prevention technology and U.S. uranium energy companies. The investments align with the company's strategy to finance innovation in essential industries with significant growth potential.
The uranium investments reflect PMGC's support for nuclear energy as a clean power source for reducing carbon emissions and meeting sustainable energy demands. In the fire prevention sector, PMGC has invested in a US-based company developing eco-friendly technologies to prevent fire ignition and spread.
The company commits to updating shareholders on portfolio expansion and will file required 13D SEC filings if any individual investment exceeds 4.9% ownership.
PMGC Holdings (NASDAQ: ELAB) announced that its subsidiary, Northstrive Biosciences, has signed a research agreement with a leading preclinical CRO to evaluate EL-32, a novel engineered probiotic, both alone and in combination with semaglutide for obesity treatment.
The study will assess EL-32's impact on glycemic control and body composition in diet-induced obese mice. EL-32 targets dual myostatin and activin-A pathways to preserve muscle mass during weight loss, addressing a significant limitation of current GLP-1 receptor agonists, which can cause 40-60% of weight loss to come from lean body mass.
The CRO will provide study results and a detailed report within three months of completion. Previous preclinical data has shown that EL-32 administration resulted in statistically significant improvements in physical muscular function and body composition.
PMGC Holdings Inc. (Nasdaq: ELAB) has secured approximately $1.9 million in gross proceeds through a warrant inducement agreement with institutional investors. The agreement involves the exercise of Series A warrants issued on September 24, 2024, allowing investors to purchase 969,385 shares at an amended price of $2.00 per share.
As part of the transaction, PMGC will issue new unregistered warrants to purchase an additional 969,385 shares at $2.75 per share, exercisable upon shareholder approval with a five-year expiration term. The company will file a registration statement with the SEC within 30 days for the resale of shares from the new warrants. The transaction, with Univest Securities as financial advisor, is expected to close around January 28, 2025.
Northstrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ: ELAB), has been invited to present at UCLA's exclusive symposium on Anti-Obesity Treatments: Challenges and Emerging Solutions. The company will showcase EL-22, their groundbreaking engineered probiotic designed to preserve muscle mass during weight loss treatments.
The symposium, organized by UCLA Metabolism Theme at David Geffen School of Medicine, brings together leading obesity clinicians, researchers, drug developers, and investors. EL-22 addresses a critical challenge in current obesity treatments, particularly with GLP-1 receptor agonists, where 30-50% of body weight lost is lean muscle mass—a side effect without approved treatments.
The presentation is scheduled for February 7th at 11:30 am PT, where Northstrive Biosciences aims to connect with key opinion leaders, investors, and established pharma companies in the obesity space.
PMGC Holdings Inc. (NASDAQ: ELAB) has completed the divestiture of its wholly owned subsidiary Elevai Skincare Inc. to Carmell The transaction includes:
- Approximately $1.1 million in Carmell common stock (1,267,040 total shares at $0.8488 per share)
- Around $57,000 in cash upon sale of specified inventory
- Assumption of Elevai's contractual liabilities and trade payables
- 5% royalty on net sales from existing products for 5 years
- $500,000 milestone payment if hair/scalp products reach $500,000 in revenue within 24 months
The strategic divestment aims to reduce cash burn and enhance operational efficiency. Following the closing, PMGC's outstanding common stock totals approximately 3.07 million shares.
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the renaming of its wholly owned subsidiaries as part of a strategic realignment. Elevai Research Inc. has been renamed to PMGC Research Inc., which focuses on public-private collaborations leveraging research grants. Elevai Biosciences Inc. has been rebranded as Northstrive Biosciences Inc., a biopharmaceutical company targeting obesity with next-generation treatments. These changes reflect the company's evolution as a diversified holding company.
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the sale of its skincare subsidiary, Elevai Skincare, as part of its strategic transformation. The divestiture will strengthen the company's balance sheet through approximately $1.1 million in Carmell stock and a 5% royalty on skincare revenues over the next five years, plus milestone payments.
The sale reduces operational losses and positions PMGC for new growth opportunities. The company maintains three subsidiaries: Elevai Biosciences, focusing on aesthetic medicines including EL-22 for muscle preservation during weight loss treatments; Elevai Research, utilizing Canadian research grants; and PMGC Capital , a multi-strategy investment vehicle.
The company aims to pursue transformative acquisitions and build a diversified portfolio focused on substantial growth and shareholder value creation.
